Sign in Subscribe
Pharmaceutical industry

Identification of Novel Allosteric Modulators for FFA2 Receptor

Strategic Insights

— 1 min read

Scientists in the United States have discovered a series of small molecule phenylacetamides that serve as novel and more potent FFA2 agonists. These compounds are specific for FFA2 over FFA1 and FFA3 and can activate both the G alpha(q) and G alpha(i) pathways in vitro. Treatment of adipocytes with these compounds resulted in G alpha(i)-dependent inhibition of lipolysis, similar to that of endogenous ligands. Furthermore, these compounds exhibited positive cooperativity with acetate or propionate and were found to have nonoverlapping binding sites with the endogenous ligands.

Key Takeaways:

  • The researchers identified a series of small molecule phenylacetamides that serve as novel and more potent FFA2 agonists.
  • These compounds are specific for FFA2 over FFA1 and FFA3 and can activate both the G alpha(q) and G alpha(i) pathways in vitro.
  • The compounds exhibited positive cooperativity with acetate or propionate and were found to have nonoverlapping binding sites with the endogenous ligands.
  • Treatment of adipocytes with these compounds resulted in G alpha(i)-dependent inhibition of lipolysis, similar to that of endogenous ligands.
  • The discovery of these compounds may serve as tools for further unraveling the physiological functions of the FFA2 receptor and its involvement in various diseases.
  • FFA2 is highly expressed in islets, a subset of immune cells, and adipocytes.

Statistics:

  • The potency of the small molecule phenylacetamides for FFA2 is in the high micromolar to millimolar concentrations.
  • The compounds were discovered through high-throughput screening (HTS) and showed specific binding to FFA2 over FFA1 and FFA3.
  • The compounds were able to activate both the G alpha(q) and G alpha(i) pathways in vitro on Chinese hamster ovary cells stably expressing FFA2.

Sources:

  • T. Lee et al., Amgen, Inc. (Identification and Functional Characterization of Allosteric Agonists for the G Protein-Coupled Receptor FFA2. Molecular Pharmacology, 2008;74(6):1599-1609)
  • Y. Li, Amgen Inc. (Contact information for inquiries regarding the study)
  • American Society of Pharmacology and Experimental Therapeutics (Publisher information for Molecular Pharmacology journal)

Read more